<code id='105A10FC98'></code><style id='105A10FC98'></style>
    • <acronym id='105A10FC98'></acronym>
      <center id='105A10FC98'><center id='105A10FC98'><tfoot id='105A10FC98'></tfoot></center><abbr id='105A10FC98'><dir id='105A10FC98'><tfoot id='105A10FC98'></tfoot><noframes id='105A10FC98'>

    • <optgroup id='105A10FC98'><strike id='105A10FC98'><sup id='105A10FC98'></sup></strike><code id='105A10FC98'></code></optgroup>
        1. <b id='105A10FC98'><label id='105A10FC98'><select id='105A10FC98'><dt id='105A10FC98'><span id='105A10FC98'></span></dt></select></label></b><u id='105A10FC98'></u>
          <i id='105A10FC98'><strike id='105A10FC98'><tt id='105A10FC98'><pre id='105A10FC98'></pre></tt></strike></i>

          fashion

          fashion

          author:explore    Page View:35375
          Adam's take main illustration
          Molly Ferguson/STAT

          Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

          MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

          advertisement

          This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars
          Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

          KristofferTripplaar/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiot

          read more
          Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
          Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

          1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint

          read more

          Gilead might be held responsible for not developing a drug

          JustinSullivan/GettyImagesTheassaultonthedevelopmentofnewlifesavingtherapiescontinuesapace.Recently,